Author(s)
Shenoi S1, Horneff G2, Cidon M3, Ramanan A4, Kimura Y5, Quartier P6, Foeldvari I7, Zeft A8, Lomax K9, Gregson J10, Mckenna SJ11, Abma T12, Campbell S13, Weiss J14, Marinsek N15, Patel D13, Wulffraat N16
1Seattle Children’s Hospital, Seattle, WA, USA, 2Asklepios Kliniken, Sankt Augustin, Germany, 3Stanford University, Palo Alto, CA, USA, 4University Hospital Bristol, Bristol, UK, 5Hackensack University Medical Center, NJ, NJ, USA, 6Hôpital Necker, Paris, France, 7Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 8Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, USA, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 10Novartis Pharma AG, Basel, Switzerland, 11Novartis Business Services, Dublin, Ireland, 12VU University medical center, Amsterdam, The Netherlands, 13Navigant Consulting, Inc., London, UK, 14Navigant Consulting Inc, London, UK, 15Navigant Consulting, London, UK, 16Wilhelmina Kinderziekenhuis, Utrecht, The Netherlands
OBJECTIVES: To examine caregivers’ treatment satisfaction and adherence with biologic treatments for SJIA METHODS: Within an international, non-interventional study to assess the burden of SJIA, a tailored questionnaire was developed to capture caregiver’s’ satisfaction with their child’s current and past biological treatment experience for SJIA. Caregiver’s satisfaction at the time of completing the questionnaire was assessed based on their perception of the efficacy, safety and convenience of each treatment and their child’s adherence to it. RESULTS: Anakinra (N=41[32%]), canakinumab (N=29[48%]) and tocilizumab (N=31[48%]) were the three biologics captured. Respondents answered based on all treatment experience, regardless of current treatment. Caregivers perceived treatment satisfaction with canakinumab was consistently high and equal to or higher than caregivers’ satisfaction with anakinra or tocilizumab. Significantly more caregivers were not stressed or anxious when their child received canakinumab (48%) and thought that canakinumab was convenient (69%), caused no burden to them (38%) and demonstrated complete improvement in symptoms (48%). In contrast, anakinra and tocilizumab were reported to be inconvenient by 58% and 48%, caused moderate to extreme burden in 64% and 71%, respectively, and anakinra had a high ‘no improvement of symptoms’ rate (24%). Overall, 41% of caregivers thought their child was not stressed or anxious receiving canakinumab compared to anakinra (12%) and tocilizumab (35%).Complete treatment compliance as follows: canakinumab (96%), anakinra (85%) and tocilizumab (81%). The main reasons for missing treatment were due to ‘forgetting to give’ or ‘forgetting to take the treatment’ in the anakinra group (17%) or the treatment was found to be ‘inconvenient for practical reasons’ in the tocilizumab group (9.8%). CONCLUSIONS: According to caregivers, biologic treatment completely improved SJIA symptoms in 48% of children on canakinumab or tocilizumab and 32% on anakinra. Canakinumab treatment was associated with higher treatment satisfaction and adherence compared to tocilizumab and anakinra for SJIA.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSY81
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Stated Preference & Patient Satisfaction
Disease
Musculoskeletal Disorders, Rare and Orphan Diseases
